QUANTITY: 13,381 tablets and capsules and 18 btls. of liquids at Daytona Beach, Fla., in possession of Morris Pharmaceuticals.

SHIPPED: On unknown dates, by various drug handlers.

LABEL IN PART: (Some labels) "Professional Sample" and "Physicians Sample."

RESULTS OF INVESTIGATION: The articles consisted of quantities of prescription drugs repacked from physicians' samples into containers having labels bearing brand names indicative of manufacture outside the State of Florida; some labels bearing the words "Professional Sample," "Physician's Sample," or similar wording; and some labels bearing the names and addresses of the manufacturers, packers, or distributors located outside the State of Florida.

LIBELED: 12–28–61, S. Dist. Fla.

CHARGE: 502(a)—while held for sale, the words "Professional Sample," "Physician's Sample," and similar wording on the labels of a number of the repacked articles of drug, were false and misleading as applied to the articles in the possession of a repacker and intended for sale and not intended for use as "complimentary–not for sale" samples for physicians and others lawfully engaged in dispensing prescription drugs; 502(b)(1)—a number of the repacked articles of drug failed to bear a label containing the name and place of business of the manufacturer, packer, or distributor; 502(e)(1)—the labels of a number of the repacked articles of drug failed to bear the common or usual name of the drugs; 502(e)(2)—the labels of a number of the repacked articles of drug failed to bear the common or usual name of each active ingredient contained therein; 502(f)(1)—the labeling of a number of the repacked articles of drug failed to bear adequate directions for use and they were not exempt from that requirement since they were subject to the provisions of 503(b)(1) and their labels failed to bear an identifying lot or control number from which it was possible to determine the complete manufacturing history as is required by regulations; and 503(b)(4)—a number of the repacked articles of drug failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 1–31–62. Default—destruction.

7010. Various prescription drugs. (F.D.C. No. 46194. S. Nos. 93–113/20 R, 96–759/60 R.)

QUANTITY: 426 assorted containers at Philadelphia, Pa., in possession of Raymon Pharmacy.

SHIPPED: On unknown dates, by various drug handlers.

RESULTS OF INVESTIGATION: The articles consisted of quantities of prescription drugs repacked from physicians' samples into bottles having labels bearing brand names indicative of manufacture outside the State of Pennsylvania, and quantities of prescription drugs which were not yet repacked, originally intended for use as samples, and still in the original sample packages bearing the words "Professional Sample," "Complimentary," or similar wording, and the names and addresses of manufacturers, packers, or distributors outside the State of Pennsylvania.

LIBELED: 7–27–61, E. Dist. Pa.

CHARGE: 502(a)—while held for sale, the sample legends appearing on the labels affixed to a number of the articles were false and misleading as applied to the articles in the possession of a repacker and intended for sale and not intended for use as "complimentary–not for sale" samples for physicians and

others lawfully engaged in dispensing prescription drugs; 502(f)(1)—the labeling of a number of the articles failed to bear adequate directions for use and they were not exempt from that requirement; and 503(b)(4)—a number of the articles of drug were subject to the provisions of 503(b)(1) and their labels failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 2-7-62. Default—destruction.

7011. Proloid tablets. (F.D.C. No. 46740. S. No. 209 T.)

QUANTITY: 5 500-tablet bags at Miami, Fla., in possession of Flamingo Wholesale, Inc.

SHIPPED: Prior to 8-10-61, from Morris Plains, N.J.

LABEL IN PART: (Bag) "Proloid ½ gr. * * * Cost 72041/500 net."

LIBELED: 11-28-61, S. Dist. Fla.

CHARGE: 502(b)(1)—while held for sale, the article failed to bear a label containing the name and place of business of the manufacturer, packer, or distributor; 502(e)(1)—the label of the article failed to bear the common or usual name of the drug; 502(f)(1)—the label of the article failed to bear adequate directions for use and the article was not exempt from such requirement since it was a drug subject to 503(b)(1) and its label failed to bear an identifying lot or control number from which it was possible to determine the complete manufacturing history of the package of the drug; and 503(b)(4)—the article was subject to the provisions of 503(b)(1) and the label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

DISPOSITION: 1-30-62. Default—destruction.

7012. Hematonic Formula capsules and B complex capsules. (F.D.C. No. 46747. S. Nos. 7-192/3 T.)

QUANTITY: 56 ctnd. btls. of *Hematonic Formula capsules* and 15 ctnd. btls. of *B complex capsules*, at Gloucester, Mass.

SHIPPED: Between 11-17-59 and 6-21-60, from Dallas, Tex.

LABEL IN PART: (Ctn. and btl.) "100 Capsules Hematonic Formula An Anti-Anemia Formula Vitamin B_{12}-B_1, Liver Stomach with Intrinsic Factors and Iron * * * Each capsule contains: * * * Folic Acid 1 Mg." and (ctn. and btl.) "100 Capsules High Potency B Complex With Vitamin B-12, Minerals, Liver, Lipotropes and Intrinsic Factors * * * Each Coated Tablet Contains: * * * Folic Acid 0.5 Mg."

LIBELED: 12-1-61, Dist. Mass.

CHARGE: 503(b)(4)—while held for sale, the article was a drug subject to the provisions of 503(b)(1) and its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription."

The article was alleged also to be misbranded under the provisions of the law applicable to foods, as reported in notices of judgment on foods.

DISPOSITION: 1-15-62. Default—destruction.

7013. Materfol Elixir. (F.D.C. No. 46461. S. Nos. 39-541/2 T.)

QUANTITY: 23 4-oz. btls. and 27 cases, each containing 12 8-oz. btls., at Santurce, P.R.